Disposition of 17500 shares by Harper Molly of Catalyst Pharmaceuticals at 22.0 subject to Rule 16b-3

CPRX Stock  USD 22.55  1.97  9.57%   
Slightly above 67 percent of all Catalyst Pharmaceuticals' investors are curious in acquiring. The analysis of the overall investor sentiment regarding Catalyst Pharmaceuticals suggests that a large number of traders are confidant. Catalyst Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Catalyst Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Catalyst Pharmaceuticals Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at zacks.com
zacks News
  
Disposition of 17500 common stock, par value $0.001 per share at 22.0 of Catalyst Pharmaceuticals by Harper Molly on 27th of November 2024. This event was filed by Catalyst Pharmaceuticals with SEC on 2024-11-27. Statement of changes in beneficial ownership - SEC Form 4

Catalyst Pharmaceuticals Current Investor Sentiment

Comfort Level 67

 Interested

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Catalyst Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Catalyst Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Catalyst Pharmaceuticals Historical Investor Sentiment

Investor biases related to Catalyst Pharmaceuticals' public news can be used to forecast risks associated with an investment in Catalyst. The trend in average sentiment can be used to explain how an investor holding Catalyst can time the market purely based on public headlines and social activities around Catalyst Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Catalyst Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Catalyst Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Catalyst Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals Fundamental Analysis

We analyze Catalyst Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Catalyst Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Catalyst Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Owned By Insiders

Shares Owned By Insiders Comparative Analysis

Catalyst Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Catalyst Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Catalyst Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Catalyst Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Catalyst Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Catalyst Pharmaceuticals Related Equities

MDGLMadrigal Pharmaceuticals   14.99   
0%
100.0%
HEPAHepion Pharmaceuticals   6.67   
0%
44.0%
VKTXViking Therapeutics   5.75   
0%
38.0%
INZYInozyme Pharma   4.13   
0%
27.0%
MREOMereo BioPharma   2.45   
0%
16.0%
EXELExelixis   1.95   
0%
13.0%
SRPTSarepta Therapeutics   1.32   
0%
8.0%
AXSMAxsome Therapeutics   0.98   
0%
6.0%
TGTXTG Therapeutics   0.45   
0%
3.0%
TERNTerns Pharmaceuticals   0.27   
0%
1.0%
AKROAkero Therapeutics   0.25   
0%
1.0%
ACADACADIA Pharmaceuticals   0.05   
1.0%
0%
INCYIncyte   0.13   
1.0%
0%
DAWNDay One   0.41   
2.0%
0%
XFORX4 Pharmaceuticals   3.27   
21.0%
0%
BTAIBioXcel Therapeutics   8.63   
57.0%
0%

Additional Tools for Catalyst Stock Analysis

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.